Effect of Genetic and Epigenetic Factors on the Clinical Response and Toxicity to Doxorubicin Among Egyptian Breast Cancer Patients
1 other identifier
observational
200
1 country
1
Brief Summary
Recent advances in technologies, such as microarray and high-throughput sequencing, represented a deeper understanding of molecular biology, especially noncoding RNA (ncRNA). It was found that there are only \<2 % of the total genome sequence as protein-coding genes while at least 98 % of the genome are transcribed into ncRNA. In the past, non-protein-coding RNAs were known as "transcription noise," but now it is obvious that ncRNAs play a crucial regulatory role in cell differentiation and organism growth and metabolism.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2020
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2023
CompletedFirst Submitted
Initial submission to the registry
January 27, 2023
CompletedFirst Posted
Study publicly available on registry
February 17, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2023
CompletedFebruary 17, 2023
February 1, 2023
2.4 years
January 27, 2023
February 8, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Cardiotoxicity
Occurrence of dilated cardiomyopathy
6 months
Secondary Outcomes (1)
Nephrotoxicity
6 months
Study Arms (2)
1
Breast cancer patients who developed cardiotoxic side effects in response to Doxorubicin treatment
2
Breast cancer patients who did not develope cardiotoxic side effects in response to Doxorubicin treatment
Eligibility Criteria
Metastatic and localized breast cancer patients treated with Doxorubicin
You may qualify if:
- Metastatic and localized breast cancer patients treated with Doxorubicin among chemotherapeutic protocol.
- Measurable disease.
- Age of 18 years to 80 years.
- The women of childbearing age must use an effective contraception for the duration of the study.
You may not qualify if:
- Breast cancer patients who had undergone radiotherapy or chemotherapy.
- Pregnant and lactating females.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to chemotherapeutic agents used.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Ain Shams University
Cairo, 11315, Egypt
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Lecturer
Study Record Dates
First Submitted
January 27, 2023
First Posted
February 17, 2023
Study Start
August 1, 2020
Primary Completion
January 1, 2023
Study Completion
April 1, 2023
Last Updated
February 17, 2023
Record last verified: 2023-02